LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Accueil・Liste d'Actions・Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc

Fermé

Secteur Soins de santé

73.5 1.62

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

73.3

Max

73.83

Chiffres clés
By Trading Economics
Revenu	-973K -16M
Ventes	17M 161M
BPA	-0.16
Marge bénéficiaire	-10.05
Employés	610
EBITDA	-6.8M -28M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+31.13 upside

Dividendes
By Dow Jones
Prochains Résultats	31 oct. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-335M 7.1B
Ouverture précédente	71.88
Clôture précédente	73.5

Sentiment de l'Actualité

By Acuity

34%

66%

290 / 365 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

72.26 / 74.48 Support & Résistance

Intra-Cellular Therapies Inc Graphique

Actualités Associées

7 sept. 2024, 09:30 UTC

Actualités

Jobs Slowdown Frustrates Investors Who Wanted Certainty on the Fed -- WSJ

7 sept. 2024, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6 sept. 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6 sept. 2024, 21:18 UTC

Actualités

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 sept. 2024, 21:05 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 sept. 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 sept. 2024, 20:39 UTC

Résultats

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 sept. 2024, 20:35 UTC

Actualités

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 sept. 2024, 20:34 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 sept. 2024, 20:11 UTC

Actualités

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 sept. 2024, 19:51 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 sept. 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 sept. 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 sept. 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6 sept. 2024, 18:27 UTC

Actualités

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 sept. 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6 sept. 2024, 18:15 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6 sept. 2024, 18:12 UTC

Actualités

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6 sept. 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6 sept. 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6 sept. 2024, 17:30 UTC

Actualités

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6 sept. 2024, 17:27 UTC

Actualités

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6 sept. 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 sept. 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6 sept. 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6 sept. 2024, 16:35 UTC

Résultats

Actions en Tendance

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6 sept. 2024, 16:33 UTC

Acquisitions, Fusions, Rachats

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6 sept. 2024, 16:20 UTC

Market Talk

Résultats

Tech, Media & Telecom Roundup: Market Talk

6 sept. 2024, 16:20 UTC

Résultats

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6 sept. 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

Comparaison

Variation de prix

Intra-Cellular Therapies Inc prévision

Objectif de Prix

By TipRanks

31.13% hausse

Prévisions sur 12 Mois

Moyen 96.43 USD 31.13%

Haut 130 USD

Bas 74 USD

Basé sur 15 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

15 ratings

Achat

Maintien

Vente

Basé sur 15 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

72.26 / 74.48Support & Résistance

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

290 / 365Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

À Propos Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is focused on the discovery, clinical development, and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company offers CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. Its lumateperone bipolar depression clinical program consists of three monotherapy studies and one adjunctive study. The Company also initiated its third monotherapy Phase III study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.